-
Optimizing the disease diagnosis and treatment management mode and innovating treatment plans were unveiled at the Expo
Time of Update: 2022-11-15
At the 5th China International Import Expo being held here, all parties have presented optimized disease diagnosis and treatment management models and innovative treatment plans. The reporter learned
-
Innovative drug research and development tends to be rational, and many pharmaceutical companies choose to "step on the brakes" in 2022
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Since the beginning of this year, many pharmaceutical companies have chosen to shrink their pipelines to withdraw funds and concentrate resources on projects with higher success rates.
-
The main focus of the pharmaceutical industry in the second half is undoubtedly high-quality innovative drug companies
Time of Update: 2022-11-15
The number of approved marketing authorization applications for innovative drugs was 69, a year-on-year increase of 130%.
The number of approved marketing authorization applications for innovative drugs was 69, a year-on-year increase of 130%.
-
Beijing adjusts the financing standards for basic medical insurance for urban and rural residents in 2023
Time of Update: 2022-11-15
Medical security bureaus and financial bureaus of each district, social affairs bureau and financial audit bureau of Beijing Economic and Technological Development Zone, and designated medical instit
-
The biomedical industry is popular, and pharmaceutical companies are accelerating the improvement of relevant technical capabilities
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Recently, Novartis announced that it will invest $300 million in next-generation biotherapeutics.
js?cdnversion='+~(-new Date()/36e5)];Recently, Novartis announced that it will invest $300 million in next-generation biotherapeutics.
js?cdnversion='+~(-new Date()/36e5)];Recently, Novartis announced that it will invest $300 million in next-generation biotherapeutics.
-
Recently, the phenomenon of "termination" of clinical development of pharmaceutical companies is still frequent!
Time of Update: 2022-11-15
For example, on October 31, pharmaceutical company ESSA Pharma announced that Johnson & Johnson/Janssen Pharma will cease a Phase I combination therapy clinical study with its lead drug candidate, EPI-7386, mainly due to patient recruitment challenges.
-
461 pharmaceutical companies compete! The net profit of 23 companies exceeded 2 billion
Time of Update: 2022-11-15
doubled, in addition, more than 60 companies lost money; In terms of revenue, 37 companies exceeded 10 billion yuan, led by Shanghai Pharmaceutical and Jointown; From the perspective of gross profit margin, 14 companies exceeded 90%.
-
List of Prohibitions on Online Sales of Drugs (Draft for Solicitation of Comments)
Time of Update: 2022-11-15
Feedback form Comprehensive Department of the State Food and Drug Administration November 2, 2022 List of Prohibitions on Online Sales of Drugs (Draft for Solicitation of Comments) (First Edition) (Established in November 2022)
-
The competitiveness ranking of national biomedical industrial parks was announced, and 6 parks in Jiangsu entered the top 20
Time of Update: 2022-11-15
On November 3, the 2022 China Biotechnology Innovation Conference, co-hosted by the China Biotechnology Development Center and the Suzhou Municipal People's Government, was held online, and the confe
-
The future prospects of innovative drugs are very clear in the prosperity of the CRO industry
Time of Update: 2022-11-15
Data show that among the 16 A-share CRO companies, the average growth rate of main business income in the first three quarters of 2022 is 81.
Data show that among the 16 A-share CRO companies, the average growth rate of main business income in the first three quarters of 2022 is 81.
-
Local TCM CRO enterprises and multinational pharmaceutical companies "join hands" to promote the international development of TCM
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Internationalization is an important way to build the international influence of Chinese medicine.
js?cdnversion='+~(-new Date()/36e5)];Internationalization is an important way to build the international influence of Chinese medicine.
js?cdnversion='+~(-new Date()/36e5)];Internationalization is an important way to build the international influence of Chinese medicine.
-
Improved new drugs ushered in the climax of research and development, and pharmaceutical companies applied for marketing
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Improved new drugs are improvements to marketed drugs, emphasizing "efficacy", with relatively high success rate, low risk, long life cycle, and rapid returns.
js?cdnversion='+~(-new Date()/36e5)];Improved new drugs are improvements to marketed drugs, emphasizing "efficacy", with relatively high success rate, low risk, long life cycle, and rapid returns.
-
Since the "Thirteenth Five-Year Plan", China has won a total of 23 national science and technology awards in the field of traditional Chinese medicine
Time of Update: 2022-11-15
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" proposes to build a high-level Chinese medicine inheritance protection and scientific and technological innovation system, and make specific arrangements to strengthen the inheritance and protection of traditional Chinese medicine and strengthen key areas to tackle key problems.
-
In order to accelerate the domestic research and development and application of new anti-tumor drugs, domestic and foreign pharmaceutical companies are cooperating more and more frequently
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];In order to strengthen and expand the R&D pipeline of anti-tumor drugs and accelerate the commercialization of products, it has become common for pharmaceutical companies to join forces in this field in recent years.
-
The head chain pharmacy is still busy with the "horse race" in the first three quarters
Time of Update: 2022-11-15
Recently, the disclosure period of the third quarterly report of listed companies, at present, the four leading chain pharmacies of Da Shenlin, Laobaimin, Yifeng Pharmacy and Yixintang have disclosed the performance of the third quarter, and the overall performance is good, among which the revenue growth rate of Da Shenlin, Laobai People, and Yifeng Pharmacy in the first three quarters is about 20%, and the net profits of the three have shown an increase trend.
-
Enwei Pharmaceutical's new listing, the cost of raw materials for the fist product Jieyin has risen!
Time of Update: 2022-11-15
Fourth, the market analysis of raw materials of Jieer Yin lotion Cnidium monnieri has not produced much new real estate this year, and the source of goods from the production area is basically exported.
-
The National Medical Insurance Bureau exposed 9 typical cases of defrauding maternity insurance funds
Time of Update: 2022-11-15
The case of Henan Anbang Human Resources Company fraudulently obtaining maternity insurance funds by Henan Anbang Human Resources Company in Yongcheng City, Henan Province In October 2021, the staff of the Yongcheng Medical Security Bureau of Henan Province found through daily supervision, medical data monitoring, big data analysis and investigation and verification that Henan Anbang Human Resources Company in Yongcheng Dongcheng District falsely declared labor relations without de facto labor relations with 13 pregnant women.
-
Multinational enterprises are constantly increasing their layout in the Chinese market!
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];In recent years, with the continuous deepening of the reform of China's pharmaceutical market and the continuous improvement of the innovation and R&D environment, multinational pharmaceutical companies are accelerating the pace of development, starting to further cultivate the Chinese market, and accelerate innovation and industrial upgrading.
-
In order to strengthen the coverage and extension of products and businesses, pharmaceutical companies are constantly "buying, buying and buying"
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Extending the industrial chain or expanding the product line through investment, acquisition and other means has become the norm in the pharmaceutical field.
js?cdnversion='+~(-new Date()/36e5)];Extending the industrial chain or expanding the product line through investment, acquisition and other means has become the norm in the pharmaceutical field.
-
The State Food and Drug Administration has promoted the comprehensive issuance of electronic licenses for convenience services
Time of Update: 2022-11-15
standards Since the pilot issuance of electronic registration certificates for medical devices in October 2020, the NMPA has successively announced the issuance of all 25 enterprise-related electronic licenses such as registration certificates for drugs, medical devices and cosmetics, and emphasized that electronic licenses have the same legal effect as paper licenses, and electronic licenses support online and offline applications in government affairs.
